First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV

first in class nrtti demonstrates potential as long acting oral prep against hiv

Sumary of First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV:

  • Islatravir, a first-in-class agent with multiple mechanisms of action and high potency against HIV, is in phase 3 clinical trials alone and in combination with doravirine as long-acting oral treatment, and recently evidenced potential in two phase 1 clinical trials as weekly, and possibly monthly oral pre-exposure prophylaxis (PrEP).
  • Co, and colleagues explain that the dosages were selected to cover those that preclinical in vitro and in vivo data projected to be clinically efficacious, while maintaining adequate safety margins determined from the preclinical toxicology data.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close